VIRON LAUNCHES POROSOME RECONSTITUTION THERAPY & IDENTIFICATION OF THE COMBINATORIAL USE OF SMALL MOLECULES AS DRUGS TO TARGET ‘UNDRUGGABLE' POROSOME PROTEINS

Viron Inc., uses a proprietary porosome reconstitution & porosome proteome-based platform technology that addresses the key limitations of conventional therapies & screening techniques, allowing the discovery of previously unknown functional protein and lipid targets involved in cell secretion, and identify small molecules that selectively bind to those targets, including undruggable targets and modulate secretory function in the treatment of diseases such as cystic fibrosis, diabetes and neurological disorders. At Viron, prior to clinical trials, the potency and efficacy of the combinatorial use of small molecule drug formulations, are first assessed in silico by their binding affinities to the target porosome proteins and or lipids, followed by studies on cell culture, human organoids and animal studies.